VistaGen Therapeutics (VTGN) Misses Q3 EPS by 22c

VistaGen Therapeutics (NASDAQ: VTGN) reported Q3 EPS of ($0.22). Revenue for the quarter came in at $410 thousand.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• AeroVironment restates quarterly financials, citing $89M goodwill error